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Introduction

Subject. Spinal cord injury (SCI) is a devastating condition affecting as many as 306,000 individuals in the US alone (http://www.brainandspinalcord.org/spinal--cord--injury/statistics.html; as of
. Beyond US soil, SCI is an all--too--common result of military combat -all with an enormous emotional, social, and financial cost to individuals and to society. Despite much needed attention over the past few decades and some significant advances, the cellular and molecular mechanisms leading to SCI are not yet clear. Purpose: A major consequence of SCI is the development of an astrocytic glial scar. Although the scar has benefits for tissue repair, it also blocks neural regeneration. Inhibitory chondroitin sulfate proteoglycans (CSPGs) are elevated in the glial scar and are a major deterrent to successful regeneration. To develop a more efficient method to accomplish CSPG degradation (than the current use of the bacterial enzyme chondroitinase), we have studied a normally occurring catabolic protein for CSPG degradation, the neural aggrecanase, ADAMTS--4. Scope: We used a two prong approach -employing studies both in vitro, and in vivo. We isolated, purified and tested aggrecanase on astrocytes in tissue culture; and tested aggrecanase constructs in an injury model in vivo, to ameliorate CSPG--induced inhibition. Studies conducted to date show a strong correlation between treatments with ADAMTS--4 and reduced sensory and motor behavioral deficits following a dorsal SCI in a rodent model. Although combination studies with chondroitinase have not yet been accomplished, the groundwork is set for this final set of experiments, and present foundation funding will allow continuation to complete this work.
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The following is a Final Report for CDMRP grant SC090248, entitled "A Better Way to Excise Inhibitory
Molecules (CSPGs) from a Spinal Cord Injury Scar to Promote Regeneration". Each point of progress is addressed in relationship to the Statement of Work provided in the original application.
Statement of Work
Overarching goal: To successfully degrade aggrecan and related CSPGs using naturally occurring ADAMTS------4, alone and in combination with the current "gold standard" (chondroitinase) to attenuate axonal inhibition, and promote plasticity and regeneration of adult neurons of the CNS.
Task 1. We will determine if aggrecanase and chondroitinase--mediated degradation of CSPGs
produced by primary rat cortical astrocytes will foster neurite outgrowth in vitro.
1a. We will confirm that primary astrocytes upregulate CSPGs in vitro in response to injury (experimentally induced by trauma and/or administration of TGF--ß (Smith and Strunz, 2006). We will also catalogue the specific PGs upregulated and their time course (months 1--4).
Neonatal rat cortical astrocyte cultures were prepared and expanded to 16 T--75 flasks grown to near confluency. The cultures were incubated for 3 days with 2.5 ng/ml TGF--ß in 5 ml of medium. Medium was collected from 16 flasks, and guanidine HCl was added to a final concentration of 4M. The cell layers were washed with PBS, and were lysed in 0.05M sodium acetate, pH 5.8, containing 4M guanidine HCl, 0.5% CHAPS and protease inhibitors. An additional two flasks of cells were lysed, and used for the preparation of total cellular RNA, for quantitative real time PCR analysis of proteoglycan mRNA. Both medium and cell layer samples were chromatographed on Sephadex G--50 equilibrated with 0.05M sodium acetate, pH 6.0 containing 0.5% CHAPS, 0.15 M sodium chloride, and 8M urea. The void fractions were applied to a column of DEAE Sephacel equilibrated in the same buffer. The column was washed, and proteoglycans were eluted using a 0.15 to 1.0 M sodium chloride gradient ( Figure 1A) . Chromatography of medium and cell layers from astrocyte cultures each revealed several peaks that were pooled, buffer--exchanged to remove urea, and concentrated. The multiple peaks are likley due to different degrees of sulfation of these proteoglycans. Dot blot analyses of pooled fractions using antibodies specific for different CSPGs were performed ( Figure 1B) . Dot blots were reacted with antibodies to aggrecan, neurocan, phosphacan, NG2, brevican, versican, G3 domain of aggrecan, and aggrecan CS--2 domain aggrecanase--generated neoepitopes GELE and KEEE (mixture of both antibodies). Analysis of the dot blot assays indicates that the isolated pools are largely mixtures of genetically distinct proteoglycans. Relevant to this study, we detected aggrecanase generated fragments in the major peak of medium--derived PGs eluting from the DEAE column (reacting with GELE/KEEE antibodies) which was also reactive with an antibody to the aggrecan G3 domain (also consistent with CS--substituted fragments having an intact C--terminus. This pool appeared to be highly inhibitory to neurite outgrowth (see Figure 4C ).
All of these proteoglycan pools are being further characterized for sulfation patterns using HPLC sulfated disaccharide analyses (analysis in progress at Glycotechnology Core Resource, UC Davis). These PG fractions have been used for analysis of neurite outgrowth inhibitory activity using an assay developed in our laboratory.
We optimized a commercially available assay for high--throughput neurite outgrowth analysis (Cellomics Neurite Outgrowth Kit) to measure the inhibitory effects of substratum bound proteoglycans on neurite outgrowth. In this assay, NeuroscreenTM--1 (NS--1) cells, a derivative of the PC12 cell line, were plated in a 96--well plate, and each well was treated with increasing concentrations of NGF to stimulate neurite outgrowth (Figure 2) . To test the effect of CSPGs on outgrowth, plates were incubated with serial dilutions of proteoglycan prior to plating. Adsorbed PG was quantified by ELISA assay on duplicate plates.
Following two days of outgrowth, cells were fixed and stained to reveal nuclei and neurites, which were detectible at different fluorescent wavelengths. A microscope with a motorized, computer--driven stage was used to obtain multiple images per well of nuclei and neurites. These images were analyzed using the Neurite Tracer plugin with Image J software. Neurite outgrowth normalized to cell number was plotted vs. NGF concentration for each concentration of proteoglycan adsorbed to the plate surface. In this manner, we obtained curves to quantify neurite inhibition as a function of proteoglycan concentration. We examined the inhibitory activity due to chondroitin sulfate, keratan sulfate, and N--linked oligosaccharides (Figure 3) . We observed that chondroitinase ABC degradation of aggrecan on the plate surface enhances neurite outgrowth, as expected from the results of this and other laboratories. We obtained new data suggesting that removal of KS chains further enhances outgrowth. After degrading both chondroitin sulfate and keratan sulfate, we digested the substrate bound aggrecan with peptide--N--glycosidase F, which cleaves N--linked oligosaccharides from the core protein. This treatment resulted in a further enhancement of neurite outgrowth. These data are currently being prepared for publication.
We have performed neurite outgrowth assays to determine the effect of the different pools of astrocyte proteoglycans shown in Figure 1 upon neurite outgrowth (Figure 4) . In this experiment we confirmed our previous result showing a dose--response relationship between substrate--bound aggrecan and neurite 04/07/2014 outgrowth. We observed that the astroctye cell layer--derived PGs tend to enhance neurite outgrowth, an effect that become more pronounced in the later, more highly negatively charged fractions. We further observed that medium--derived proteoglycans tend to be inhibitory in the more highly negatively charged fractions. These data correlate with results of the sulfated disaccharide analysis, and the characterization of genetically distinct proteoglycans. places an ADAMTS--4 insert having a C--terminal FLAG sequence in the vector pcDNA3.1. The protein product can be affinity purified on a anti--FLAG affinity matrix, and can be detected on a Western blot using an anti--FLAG primary antibody. Each construct can be transiently or stably transfected into mammalian cells.
To produce recombinant ADAMTS--4 protein for experiments in vitro, or for injection into rat spinal cord injury sites (for Task 2a), we transiently transfected the 703 construct (having a C--terminal FLAG tag) into HEK293T cells for protein expression. This cell line was chosen because it is commonly used for high--level recombinant protein expression. In addition, we and others have found that the HEK293T cell line has characteristics of neuronal progenitor cells. We have found that this cell line produces proteoglycans characteristic of the CNS, including aggrecan, versican, decorin, neurocan, NG--2 and phosphacan. When transfected with the ADAMTS--4 expression plasmid, we found high levels of recombinant protein expression, and discovered that the cells themselves produce ADAMTS4 endogenously. The recombinant ADAMTS4 was found in both the cell layer and the medium. The enzyme in the medium, however, appeared to be in a complex with a high molecular weight material that is likely aggrecan or another CSPG. Examination of the western blot following colloidal gold staining, to reveal all of the protein in each lane, showed a reduction in very high molecular weight protein in the cell lysate and the medium from ADAMTS4--transfected cells. This suggested that aggrecan, or other CSPGs produced by the HEK293 cells were actually being degraded by the expressed protease.
Subsequently, another western blot analysis of lysate and medium from the same experiment showed the presence of ADAMTS4--generated aggrecan fragments, using an antibody to a specific neoepitope (anti--NITEGE) found on aggrecanase--generated aggrecan fragments. This fragment was seen in non--transfected lysates, apparently due to the endogenous ADAMTS4 activity, but was significantly increased in the medium from transfected cells. We regard this result as proof of principle for future experiments, which will be to express ADAMTS4 in glial scar to reduce the content of neurite outgrowth--inhibitory CSPGs. We purified recombinant ADAMTS4 from transfected HEK293 medium. Following transfection, HEK293 cells were incubated in medium containing heparin, to antagonize the strong association of ADAMTS--4 with PGs in the cell layer and medium. The enzyme was then purified using FLAG antibody--conjugated magnetic beads.
The pBOB/ADAMTS--4/FLAG construct lacks a reporter gene, so SDS--PAGE and Western blot analyses were 
Preparation of pLVX--Tet--On Advanced, and pLVX--Tight--Pur--ADAMTS--4 vectors.
We had the original goal of developing a lentiviral expression system that would enable the inducible expression of ADAMTS4 in primary cultured astrocytes, as well as inducible expression in vivo, in a rat model of spinal cord injury. However, this system was fraught with problems (some we overcame), but good practices dictated we abandon this direction. We used only the His--tagged and Flag--tagged expression constructs to accomplish our goals both in vitro and in vivo.
1c. Using the above system, we will determine if aggrecanase--mediated degradation of CSPGs in primary rat cortical astrocytes induces growth--inhibiting (CSPG--producing) astrocytes to become growth permissive (CSPG--degraded), and thereby foster regeneration of adult neurons (CST, RST, DC (DRG)) (months 8--11).
We examined PG production and enzyme degradation of PGs in a co--culture model using transduced primary neurons and primary injured astrocytes. We cultured primary rat astrocytes as described previously with and without TGF--ß (5ng/ml, 48 H ; activates astrocytes and induces them to upregulate proteoglycans, i.e. simulates injury). Primary chicken DRG neurons (E9) were grown on confluent monolayers of these astrocytes, or in sparse cultures such that the neurons adhered to laminin or PLO first, then encountered 04/07/2014 transfected astrocytes Figure 4 shows a representative image of DRG neurons and astrocytes in co--culture, demonstrating the basic paradigm. The co--cultures were then fixed and labeled with βIII--tubulin (TRITC) to image neurons, and GFAP (Cy5) 1° Ab's to image astrocytes, and DAPI to label all nuclei. (Figure 7 ; 40X).
Quantitative analyses were performed, but are yet inconclusive. A larger sample size is required.
1d. We will test the responses of other neurons, e.g. 5HT, which have been shown to be robust following SCI in previous studies (months 12--13). Using the NS--1 neurite outgrowth assay, we will determine CSPG production (ELISA), CSPG cleavage (Western blot analyses), and aggrecanase activity (enzyme activity assays and immunostaining for neoepitopes) ( Further, we will isolate aggrecanase--generated fragments and test their effect(s) on elongating axons in vitro.
For a variety of reasons, we limited our analyses throughout the study to only DRG neurons, the most relevant of the neuron types listed for this study, and the one to which we have the most previous data for comparison. We also tested NS--1 cells (see outgrowth assays above).
Aggrecanase--generated fragments were not tested in vitro, but are the focus of a renewed study. Lentiviral preparation, and issues were discussed above.
Aggrecanase for studies in vivo. In preparation for injection in vivo, it was necessary to show that the His--tagged aggrecanase was active. We used both active and heat--inactivated aggrecanase for digestion of recombinant aggrecan, the results of which are shown in that the enzyme we were injecting in vivo following the dorsal hemisection spinal cord injury was active. Surgical Procedures. All animal studies were conducted according to a University of Kentucky, IACUC--approved and DOD--approved protocol (#2010--0702). Adult male Sprague--Dawley rats (300--350g) were anesthetized with isoflurane (2--3% oxygen). Prior to the injury, a silastic tubing catheter (Figure 9 ) was placed in the intrathecal space through a small hole in the dura between the T1 and T2 vertebrae. The tubing was anchored to the T2 dorsal process and surrounding muscle via suture and Vetbond (3M), and was attached to an Azlet osmotic minipump containing pharmacological treatment, which was placed subcutaneously. The surgical procedure for the injury was initiated by performing a laminectomy of the caudal half of C5 and the rostral half of C7 vertebrae to expose the C6 and C7 dorsal roots. (Figure 10 and 11) . This injury produced a lesion that included the dorsal columns (sensory) and a portion of the corticospinal tracts (motor). Chondroitinase: A major goal of this study was to use combinational therapy (aggrecanase + chondroitinase (cABC)) to promote regeneration in vivo. One setback for this study was that our aggrecanase lentivirus was prepared using a different backbone than the chondroitinase lentiviral vector, supplied by the Smith lab (George Smith, PhD: colleague and previous collaborator). Taking advantage of the lentivirus expertise within SCoBIRC (Charles Mashburn, PhD), our ADAMTS--4 insert has also been cloned into a second construct, pCSC--SP--PW, which matches the construct used to generate the cABC lentivirus. This protocol will result in fewer experimental variables.
As we did for aggrecanase, we confirmed chondroitinase activity compared to a heat--inactivated control (Figure 12) . We are just now ready for combinational studies in vivo with aggrecanase, but have reached the end of DOD funding. We have obtained foundation funding to finish this phase of the study. All data show that active enzyme was successfully delivered to the sites of injury.
2c. Histological assays to identify all cell types and molecules of interest in vivo. (months 25--28)
See 2b.
04/07/2014 2d. Behavioral assays. Repeat in vivo paradigm and test behavioral recovery using the Reach, Grasp and Pellet Retrieval test (motor), the Grid Walking test (motor), and the Sticker Attention test (sensory) (months 29--36).
Two behavioral tests were performed to assess forelimb function after injury. All rats underwent acclimation and acquisition procedures prior to SCI.
Staircase Pellet
Retrieval Test: Rats were tested three days a week specifically on Monday, Wednesday, and Friday. The day before testing food pellets were removed from the rat housing, leaving them without food for 18--24 hrs. Three times per week, rats were trained on the task for a total of 4 weeks. The first week of training rats were positioned above a trough filled with 45 mg dustless precision purified food pellets (Bio--Serv, Inc.) for 15 minutes each weekday for 1 week. The following week, rats retrieved pellets from the staircase apparatus for a 10 min session each weekday for 1 week. For the following two weeks, rats retrieved pellets during a 5--minute session. For the last three days of training, the number of pellets retrieved were recorded and used as a baseline measure for the analysis. Testing after SCI was similarly conducted (5 min. sessions) beginning 1 week after injury, once a week, and food was always removed the day prior to testing.
Sensory Sticker Test:
Four weeks following injury, rats were subjected to the sensory sticker test. A 6 mm--diameter AVERY® self--adhesive color--coding sticker was applied to each forepaw palmar surface. Rats were then placed into a clean cage without bedding, and the time until the rat rotated the paw dorsally to expose the palmar surface to its mouth was measured. The maximum duration of each trial was 2 minutes. Five trials were conducted each with a 1--minute interval between trials. The attention times of the last 4 trials were averaged to assess sensory recovery.
Recombinant ADAMTS--4 cleaves aggrecan and enzymatic activity is lost upon heat inactivation.
The results of the behavioral tests to date have been encouraging. The dorsal hemisection SCI at C6/7 in rat causes an impairment of the fine mechanical sensory systems and moderate motor impairment in the forepaw (due to limited penetration of Vibraknife into corticospinal tracts). Sensation was tested using the Sticker Sensory Task (Figure 16) , and was done only after the final motor test, due to behavioral acclimation. Figure 16 shows there is a significant increase in the time an injured rat first notices the sticker placed on its paw. However, treatment with a recombinant aggrecanase abolished this increase and returned it to an interval not statistically different from uninjured animals. Figure 16 shows that over a course of 5 trials, the injured animals (both those receiving active aggrecanase and those not) showed reduced latency though not returning to uninjured sham levels. However, a trend suggested that aggrecanase treatment reduces the amount of time till first notice in the initial trials, likely before the animals get acclimated to the test. Figure 17 shows results of the Staircase Retrieval task, an indication of forepaw use for reaching, grasping and retrieving food to the endpoint of successful consumption of food pellets. These data show significant improvement in the Staircase Retrieval test with 14--day aggrecanase administration. Future studies using aggrecanase and chondroitinase combined will determine if the two enzymes together show synergistic results, above that for just aggrecanase alone.
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Personnel:
Personnel in addition to the PI who contributed to the studies, either throughout the project, or for some 1"""""2"""""3""""""4"""""5" . Treatment with active ADAMTS--4 had no effect on performance during the staircase pellet retrieval task following dorsal hemisection. Following dorsal hemisection, there was a significant decrease in the number of pellets retrieved at week 1 and 2 of the left paw and at week 1,2, and 3 of the right paw, indicating a grasp and retrieval deficit, likely due to the injury of the CST and RST. Treatment with active ADAMTS--4 did not significantly improve this performance. Data was analyzed using a two--way ANOVA (by Treatment and Time) followed by Bonferroni post--hoc analysis. * p<0.05, ** p<0.01, *** p<0.001, ns --no significant difference. 
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Key research accomplishments
• Removal of KS chains further enhanced NS--1 outgrowth, beyond that of chondroitinase treatment alone • Further degradation with peptide--N--glycosidase F, which cleaves N--linked oligosaccharides from the core protein, resulted in a further enhancement of NS--1 neurite outgrowth • Establishment of a high--throughput technique for assessing the effects of HEK293T cell (glial like) chondroitin sulfate proteoglycans.
• Successful diffusion of recombinant aggrecanase into spinal cord tissue at the site of injury and assessment of resulting neurite behavior • Aggrecanase treatment reduces the severity of motor and sensory deficits following C6/7 spinal cord (dorsal hemisection) injury. 
Conclusions
Importance of implications of completed research: We have generated the specific tools and methodologies necessary to test aggrecanase and chondroitinase in vitro and in vivo. We have done studies to optimize the in vivo model and enzyme delivery methods. We have introduced aggrecanase in vivo using a dorsal hemisection injury model in the rodent and have processed spinal cord tissues to examine cellular and molecular changes. We have assessed motor and sensory deficits following injury without aggrecanse treatments (controls) and have shown that treatment with aggrecanase can partially alleviate these deficits. 
